Analysts Set Aquinox Pharmaceuticals Inc (AQXP) PT at $18.50
Shares of Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) have earned an average recommendation of “Buy” from the six brokerages that are presently covering the stock. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $18.50.
AQXP has been the subject of a number of recent research reports. Zacks Investment Research downgraded shares of Aquinox Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 17th. Cantor Fitzgerald reissued an “overweight” rating and set a $28.00 price objective on shares of Aquinox Pharmaceuticals in a research report on Saturday, March 11th.
Shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) traded down 0.14% during midday trading on Monday, reaching $14.12. The company had a trading volume of 54,513 shares. Aquinox Pharmaceuticals has a one year low of $6.01 and a one year high of $19.97. The company has a 50 day moving average of $16.09 and a 200 day moving average of $15.44. The company’s market capitalization is $330.73 million.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last issued its quarterly earnings data on Thursday, March 9th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.03. Analysts predict that Aquinox Pharmaceuticals will post ($2.22) EPS for the current fiscal year.
Large investors have recently modified their holdings of the stock. TD Asset Management Inc. acquired a new stake in shares of Aquinox Pharmaceuticals during the third quarter worth about $1,052,000. BlackRock Advisors LLC increased its stake in shares of Aquinox Pharmaceuticals by 31.1% in the third quarter. BlackRock Advisors LLC now owns 530,373 shares of the company’s stock worth $7,086,000 after buying an additional 125,798 shares during the last quarter. BlackRock Inc. increased its stake in shares of Aquinox Pharmaceuticals by 32.0% in the third quarter. BlackRock Inc. now owns 66,792 shares of the company’s stock worth $892,000 after buying an additional 16,192 shares during the last quarter. BlackRock Group LTD increased its stake in shares of Aquinox Pharmaceuticals by 15.9% in the third quarter. BlackRock Group LTD now owns 232,002 shares of the company’s stock worth $3,100,000 after buying an additional 31,902 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in shares of Aquinox Pharmaceuticals by 227,925.0% in the third quarter. Tower Research Capital LLC TRC now owns 9,121 shares of the company’s stock worth $122,000 after buying an additional 9,117 shares during the last quarter. 97.78% of the stock is owned by hedge funds and other institutional investors.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Receive News & Ratings for Aquinox Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.